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What effect do inhaled
steroids have on delaying 
the progression of COPD?
■ EVIDENCE-BASED ANSWER
The annual rate of decline in forced expiratory
volume for 1 second (FEV1) has been researchers’
gold standard as an objective measure for pro-
gression of chronic obstructive pulmonary disease
(COPD). Inhaled corticosteroids (ICS) do not con-
sistently have a statistically significant impact on
FEV1 decline, and thus on the progression of
COPD (strength of recommendation [SOR]: B, 
2 conflicting meta-analyses and numerous con-
flicting randomized controlled trials). In those
studies that did show improvements in FEV1
decline, the change does not appear to be clinical-
ly significant (7.7 to 9.0 mL/year). 
These findings do not take into account the
potential impact of ICS on such patient oriented
outcomes as exacerbation rates, quality of life,
outpatient visits, hospitalization, and mortality.  
■ EVIDENCE SUMMARY
No therapies are known to improve long-term
lung function in COPD; the goal of disease-
moderating therapy is therefore to slow the rate
of decline compared with the expected rate. All
of the studies reviewed used FEV1 as an objec-
tive measure of whether ICS reduce this rate of
decline in lung function.
Two recent meta-analyses evaluating medi-
um- to high-dose ICS effects on FEV1 decline
provided conflicting results. One meta-analysis
evaluated 8 controlled clinical trials lasting at
least 2 years (n=3715) and found that, when
compared with placebo, ICS significantly
reduced the rate of FEV1 decline by 7.7 mL/year
(P=.02) and that high-dose ICS had a greater
effect of 9.9 mL/year (P=.01).1 Another meta-
analysis of 6 randomized, placebo-controlled tri-
als with a duration of at least 2 years (n=3571)
found a nonsignificant trend in favor of ICS,
with a difference in FEV1 decline of 5.31
mL/year (P=.08) between the ICS and placebo
groups.2
The differences observed in these 2 meta-
analyses may be explained by the authors using
slightly different approximations to the stan-
dard error, applying slightly different statistical
analytical methods, and using different inclu-
sion criteria for trials. However, 5 of the trials in
these reviews were the same. Both meta-analy-
ses determined only rate of lung function
decline and did not evaluate clinical outcomes. 
A trial not included in the previously men-
tioned meta-analyses evaluated post-bron-
chodilator FEV1 decline in 48 patients with early
signs and symptoms of COPD for 2 years.3
Subjects were assigned to medium-dose flutica-
sone propionate or placebo. Early initiation of
ICS treatment did not affect the progressive
deterioration of lung function as no modifying
effect on annual FEV1 decline was observed,
however, the study only had power to detect a
60-mL annual drop in FEV1. 
Meta-analyses and trials evaluating COPD
progression have focused on a disease-oriented
outcome (the rate of FEV1 decline). However,
patient-oriented outcomes such as exacerbation
frequency, hospitalization, health-related quali-
ty of life, and mortality might be more important
measures of successful therapy. Although such
patient-oriented outcomes are not the focus of
this review or the included meta-analyses, a few
of the small randomized controlled trials includ-
ed in these meta-analyses suggest that ICS may
improve such patient-oriented outcomes.
Notably, exacerbation rates significantly
decreased by 25% (P=.026), and health status
improved (P=.0043) among patients with 
moderate to severe COPD who were taking flu-
ticasone compared with those taking placebo.4
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■ CLINICAL COMMENTARY
Smoking cessation a huge benefit 
to all COPD patients
In adults aged more than 30 years old with
COPD, the physiological abnormality is primari-
ly an accelerated decline in the FEV1 from the
normal rate of about 30 mL per year to nearly
60 mL per year. In patients with COPD, smok-
ing cessation is the only proven means to slow
down the progression of the disease, with up to
a sustained 50% reduction in the rate of lung-
function decline. 
Therefore, it is imperative for family
physicians to underscore the magnitude of the
benefit of smoking cessation to all COPD
patients and to emphasize the current evidence
that inhaled corticosteroid has a limited impact
in delaying the progression of the disease.
Vincent Lo, MD, St. Elizabeth Family Medicine
Residency Program, Utica, NY; SUNY Upstate Medical
University, Syracuse
In mild to moderate COPD, patients treated
with triamcinolone had fewer respiratory symp-
toms (P=.005), fewer visits to a physician
because of respiratory illness (P=.003), and
improved airway reactivity (P=.02).5 Some sys-
tematic reviews and other randomized trials
suggest that ICS have significant benefit on
these patient outcomes.6
■ RECOMMENDATIONS FROM OTHERS
Scientists from the National Heart, Lung, and
Blood Institute and the World Health
Organization provided an update of the Global
Initiative for Chronic Obstructive Lung Disease
(GOLD) in 2003.7 They reported that regular
treatment with ICS does not modify the long-term
decline of FEV1 in patients with COPD. However,
they recommended treatment with ICS for symp-
tomatic COPD patients with an FEV1 less than
50% of predicted (stage III: severe COPD and
stage IV: very severe COPD) and repeated exac-
erbations (ie, 3 in the last 3 years). Guidelines
from other countries also suggest that ICS do not
affect the progression of COPD, but support the
use of ICS for patients with severe COPD and
repeated exacerbations.8–10
Laura Hansen, PharmD, James Havemann, MD,
Martha Burroughs, MLS, University of Colorado 
Health Sciences Center, Denver
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